Clinical Trial 21630

• Overview

  Study Title:

  Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab with or without Chemotherapy in Black Patients with NSCLC

  Objective:

  PRIMARY Cohort 1 * To determine real-world overall survival (rwOS) among Black patients with advanced/metastatic NSCLC treated pembrolizumab ± chemotherapy. Cohort 2 * To determine progression-free survival (PFS) among Black patients with advanced/metastatic NSCLC treated with pembrolizumab ± chemotherapy by a biomarker driven approach. Secondary: Cohort 1 * To evaluate rwTTD and rwTTNT among Blacks with advanced/metastatic NSCLC receiving pembrolizumab ± chemotherapy per SoC. * To evaluate the effect of baseline ctDNA burden on the efficacy endpoint of real-world overall survival in Black patients with advanced/metastatic NSCLC receiving pembrolizumab ± chemotherapy. * To assess disparities in biomarker testing rates in Black patients with NSCLC. * To assess patient activation and engagement via study questionnaires. * To assess provider perceived barriers to broad utilization of comprehensive biomarker testing in Black Patients with lung cancer. Cohorts 2a and 2b * To determine ORR and OS among Black patients with advanced/metastatic NSCLC. * To identify/quantitate ctDNA dynamics in Black patients being treated with pembrolizumab and pembrolizumab chemotherapy combinations. * To evaluate the safety of pembrolizumab ± chemotherapy with corresponding endpoints of AEs and SAEs. * To assess patient activation and engagement via study questionnaires. * To identify time-to-event metrics indicative to Black patients with Advanced/ metastatic NSCLC * To develop radiomic profiles of Black patients with Advanced/metastatic NSCLC

• Treatments

  Therapies:

  Chemotherapy (NOS); Immunotherapy

  Medications:

  Abraxane (); Alimta (Pemetrexed); Nab-paclitaxel (Abraxane); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); cisplatin (); paclitaxel ()

• Inclusion Criteria

  Key Inclusion Criteria:
  • Be willing and able to provide written informed consent/assent.
  • Must be ≥ 18 years of age on day of signing informed consent.
  • Be Black / African American per self-report.
  • Have an ECOG performance status of 0- 2.
  • Have histologically or cytologically confirmed, advanced/metastatic NSCLC.
  • Be treatment naïve in the advanced/metastatic/recurrent disease setting.
  • No known EGFR/ALK/ROS1 tumor mutations. Liquid biopsies are acceptable.
  • Patients who received platinum-containing adjuvant chemotherapy, neoadjuvant chemotherapy or definitive chemoradiation and/or neoadjuvant and/or adjuvant immunotherapy and/or consolidation immunotherapy therapy given for locally advanced disease and developed recurrent (local or metastatic) disease ≥ 6 months of completing therapy are eligible.
  • Be planned/eligible to receive first-line therapy in the advanced/metastatic setting.
  • Have testing status for PDL1 tissue status.
  • Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with any grade endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible.
  • Adequate organ function
  • Female subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of the study through 180 days after the last dose if treated with pembrolizumab plus chemotherapy, or 120 days after the last dose if treated with pembrolizumab monotherapy. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
  • Male subjects should agree to use an adequate method of barrier contraception starting with the first dose of study therapy through 180 days after the last dose if treated with pembrolizumab plus chemotherapy.
  • Other inclusion criteria may apply.

• Exclusion Criteria

  Key Exclusion Criteria:
  • Does not plan or is ineligible to receive pembrolizumab with or without chemotherapy per institutional standard/treating provider.
  • History of allogenic tissue/solid organ transplant.
  • Received prior treatment chemotherapy and/or immune checkpoint inhibitor therapy in the advanced/metastatic setting for lung cancer.
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy at doses ≥ 10 mg prednisone or any other form of systemic immunosuppressive therapy at C1D1. Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted (i.e., ≤ 10 mg/day prednisone equivalents). A brief course (≤ 7 days) of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted.
  • Has active autoimmune disease that has required active systemic treatment in the past 2 years [i.e., with use of disease modifying agents, corticosteroids in doses greater than 10 mg of prednisone daily (or equivalent) or immunosuppressive drugs]. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.
  • Has an active infection requiring systemic therapy.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, that would substantially increase the risk of incurring adverse events (AEs) from the study medications, that would interfere with the subject’s participation for the full duration of the study or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  • Has received a live vaccine within 30 days of planned start of study therapy.
  • Has received an investigational agent or has used an investigational device within 3 weeks prior to study intervention administration.
  • History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has known untreated central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they have completed radiation therapy (where applicable), are clinically stable and have not required steroid treatment at ≥ 10 mg of prednisone for at least 3 days prior to the first dose of study intervention.
  • Severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients or has a known sensitivity as applicable to carboplatin, cisplatin, taxane or pemetrexed.
  • Other exclusion criteria may apply.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.